|
GSK picks up NICE recommendation for Strimvelis, a €594000 gene therapy
FiercePharma Despite being one of the most expensive drugs in the world, GlaxoSmithKline's gene therapy Strimvelis won the backing of the often stingy U.K. cost watchdogs to treat a rare disease called ADA-SCID, or "bubble boy" syndrome. The drug, which costs … |
|
GSK picks up NICE recommendation for Strimvelis, a €594000 gene therapy
FiercePharma Despite being one of the most expensive drugs in the world, GlaxoSmithKline's gene therapy Strimvelis won the backing of the often stingy U.K. cost watchdogs to treat a rare disease called ADA-SCID, or "bubble boy" syndrome. The drug, which costs … |
|
GSK picks up NICE recommendation for Strimvelis, a €594000 gene therapy
FiercePharma Despite being one of the most expensive drugs in the world, GlaxoSmithKline's gene therapy Strimvelis won the backing of the often stingy U.K. cost watchdogs to treat a rare disease called ADA-SCID, or "bubble boy" syndrome. The drug, which costs … |
